Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 20/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29473528 | 0.89 | MAP3K5 (1.00) | MAP3K5 | |
| SCHEMBL945832 | 0.89 | MAP3K5 (1.00) | MAP3K5 | |
| SCHEMBL946125 | 0.87 | MAP3K5 (0.69) | MAP3K5 | |
| SCHEMBL946755 | 0.82 | MAP3K5 (0.78) | MAP3K5 | |
| SCHEMBL943924 | 0.82 | MAP3K5 (0.78) | MAP3K5 | |
| SCHEMBL30444353 | 0.81 | MAP3K5 (1.00) | MAP3K5 | |
| SCHEMBL21706164 | 0.81 | MAP3K5 (1.00) | MAP3K5 | |
| SCHEMBL12946065 | 0.81 | MAP3K5 (0.77) | MAP3K5 | |
| SCHEMBL945441 | 0.81 | MAP3K5 (1.00) | MAP3K5 | |
| SCHEMBL945176 | 0.80 | MAP3K5 (0.76) | MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133203-A1 | METHODS OF TREATING LIVER DISEASE | GILEAD SCIENCES, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20170273952-A1 | METHODS OF TREATING LIVER DISEASE | GILEAD SCIENCES, INC. | 2017-09-28 | — | — | US | disclosed |
| US-20160166556-A1 | METHODS OF TREATING PULMONARY HYPERTENSION | GILEAD SCIENCES, INC. | 2016-06-16 | — | — | US | disclosed |
| US-20150342943-A1 | METHODS OF TREATING LIVER DISEASE | GILEAD SCIENCES, INC. | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273952-A1 | METHODS OF TREATING LIVER DISEASE | SLC10A1, FXR1, SLC10A2 | MAP3K5 174/4885 |
| US-20150342943-A1 | METHODS OF TREATING LIVER DISEASE | LOXL1, LOXL2, LOXL3 | MAP3K5 117/4885 |
| US-20160166556-A1 | METHODS OF TREATING PULMONARY HYPERTENSION | ROCK1, ROCK2, PRKCH | MAP3K5 96/4885 |
| US-20180133203-A1 | METHODS OF TREATING LIVER DISEASE | SLC10A1, FXR1, SLC10A2 | MAP3K5 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.